Drug Profile
JNJ 17299425
Alternative Names: JNJ-17299425Latest Information Update: 02 Apr 2013
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Neuropsychotherapeutics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain injuries
Most Recent Events
- 01 Aug 2008 Discontinued - Phase-II for Brain injuries in Belgium (IV)
- 01 Aug 2008 Discontinued - Phase-II for Brain injuries in France (IV)
- 01 Aug 2008 Johnson & Johnson terminates phase II trial in Brain injuries in Belgium & France due to reprioritisation of company activities (NCT01814982)